Company intelligence / Profile preview

SLEH

New York City, New York, United Statesstlukeshealth.org ↗

Ownership: Private
Development stage: Other

Overview

SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing novel therapeutics for a broad range of cancer indications. Its lead product candidate galinpepimut-S targets the WT1 protein and is being evaluated in multiple cancers including acute myeloid leukemia and mesothelioma. Another key program, SLS009 (tambiciclib), is a selective CDK9 inhibitor with promising preclinical efficacy in ASXL1-mutated colorectal cancer lines.

Therapeutic areas: HematologyOncology
Modalities: Cancer immunotherapeutic agentSmall molecule
Industry: Biotech

Partnerships

Not specified in provided results; likely includes academic collaborations given SAB appointments.

Beyond the preview

Go deeper on SLEH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLEH.

Explore the full profile